Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
02 Abril 2024 - 8:00AM
Business Wire
Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical
company pioneering a new and differentiated class of therapeutics
based on its proprietary bicyclic peptide (Bicycle®) technology,
today announced that management will participate in a fireside chat
at the 23rd Annual Needham Virtual Healthcare Conference on April
9, 2024, at 11 a.m. ET.
A live webcast of the fireside chat will be accessible from the
Investor section of the company’s website at
www.bicycletherapeutics.com. A replay of the webcast will be
archived and available following the event.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical
company developing a novel class of medicines, referred to as
Bicycle® molecules, for diseases that are underserved by existing
therapeutics. Bicycle molecules are fully synthetic short peptides
constrained with small molecule scaffolds to form two loops that
stabilize their structural geometry. This constraint facilitates
target binding with high affinity and selectivity, making Bicycle
molecules attractive candidates for drug development. The company
is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting
Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting
EphA2, a historically undruggable target; and BT7480, a Bicycle
Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting
Nectin-4 and agonizing CD137, in company-sponsored clinical trials.
Additionally, the company is developing Bicycle® Radio Conjugates
(BRC™) for radiopharmaceutical use and, through various
partnerships, is exploring the use of Bicycle® technology to
develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in Cambridge, UK, with
many key functions and members of its leadership team located in
Cambridge, Mass. For more information, visit
bicycletherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240402089559/en/
Investors: Stephanie Yao SVP, Investor Relations and
Corporate Communications ir@bicycletx.com 857-523-8544
Media: Argot Partners Deborah Elson media@bicycletx.com
212-600-1902
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Bicycle Therapeutics (NASDAQ:BCYC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025